Clinical trials: Left Ventricular Ejection Fraction
Atrial Fibrillation, Diastolic Dysfunction
Atrial Fibrillation: Chronic Beta-blocker Use Versus As-needed Rate Control Guided by Implantable Cardiac Monitor
The goal of this study is to test the feasibility of guiding as-needed pharmacological rate control of atrial fibrillation (AF) by implantable cardiac monitors and to assess the impact of continuous beta-blocker therapy versus…
- Conditions
- Atrial Fibrillation, Diastolic Dysfunction, HFpEF - Heart Failure With Preserved Ejection Fraction
- Trial name
- NCT05745337
- Testing
- As needed pharmacological rate control with beta-blocker (metoprolol tartrate, metoprolol succinate) or calcium channel blocker (diltiazem, verapamil)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Vermont
Hypotension, Heart Failure
Dapagliflozin on Hypotensive Heart Failure Patients After Sacubitril/Valsartan Therapy
The DAPA-HF trial demonstrated that dapagliflozin was able to reduce the risk of worsening heart failure events and cardiovascular death comparing to placebo in patients with reduced ejection fraction further to standard of care.
- Trial name
- NCT04575675
- Testing
- Dapagliflozin, Sacubitril-Valsartan, Beta blocker
- Where
- Taiwan
- Volunteers
- 78 people
- Sponsor
- Cheng-Hsin General Hospital
Heart Failure
This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms
The primary objective of the study is to evaluate the effect of empagliflozin 10 mg versus placebo on exercise ability using the 6 minute walk test in patients with chronic HF with reduced ejection fraction (LVEF ≤ 40%) Secondary…
- Trial name
- NCT03448419
- Testing
- Empagliflozin
- Where
- 109 sites in United States, Australia and 9 more
- Volunteers
- 312 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Hypertension
Treatment of PH With Angiotensin II Receptor Blocker and Neprilysin Inhibitor in HFpEF Patients With CardioMEMS Device
This study will assess the impact of sacubitril/valsartan on elevated pulmonary artery (PA) pressures in patients with heart failure (HF) with preserved ejection fraction (HFpEF), measured using a previously implanted hemodynamic…
- Trial name
- ARNIMEMS-HFpEF (NCT04753112)
- Testing
- Sacubitril / Valsartan Oral Tablet [Entresto]
- Where
- Spain
- Volunteers
- 14 people
- Sponsor
- Germans Trias i Pujol Hospital
Heart Failure With Normal Ejection Fraction
Renal Hemodynamics in Patients With HFpEF
Impaired renal function and heart failure with preserved ejection fraction (HFpEF) are two often co-existing medical conditions and are known to be associated with adverse cardiovascular outcome and increased mortality.
- Trial name
- NCT03672591
- Testing
- Renal clearance examination
- Where
- 2 sites in Germany
- Volunteers
- 40 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Venous Insufficiency of Leg
SOCKNLEG Compression Stocking Kit: Physical Properties
This study evaluates physical properties of a innovative leg compression stocking compared to a standard compression stocking of the same compression strength in patients with chronic venous insufficiency clinical stadium C3 and…
- Trial name
- SOCKNLEGLCA (NCT03743597)
- Testing
- SOCKNLEG, Sigvaris COTTON
- Where
- Switzerland
- Volunteers
- 35 people
- Sponsor
- University of Zurich
Heart Failure, Ischemic Heart Failure
Endocardial Delivery for Myocardial Regeneration Using Allogeneic iPSC-derived Cardiomyocyte Spheroids for HF With Systolic Dysfunction (EMERALD Study)
The purpose of this clinical study is to evaluate the safety and efficacy of endocardial delivery of HS-001 CS into severe heart failure patients with reduced ejection fraction for 26 weeks after transplantation.
- Conditions
- Heart Failure, Ischemic Heart Failure, Ischemic Heart Disease, Dilated Cardiomyopathy (DCM)
- Trial name
- EMERALD (NCT07347197)
- Testing
- HS-005
- Where
- 5 sites in Japan
- Volunteers
- 14 people
- Sponsor
- Heartseed Inc.
Heart Failure
Sacubitril/Valsartan Versus Valsartan in Heart Failure
The objective of this study was to identify potential prognostic factors of sacubitril/valsartan vs Valsartan treatment response.
- Trial name
- NCT05881720
- Testing
- Sacubitril / Valsartan Oral Tablet, Valsartan 80 mg
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Damanhour University
Heart Failure With Reduced Ejection Fraction (HFrEF), Renal Impairment
AZD3427 Effects on Renal Perfusion in Heart Failure Patients With Reduced Ejection Fraction and Renal Impairment
The present study is designed to test the effect of AZD3427 on renal perfusion in participants with heart failure and reduced eGFR (30 to 90 mL/min/1.73m2).
- Trial name
- Re-PERFUSE (NCT06611423)
- Testing
- AZD3427, Dopamine, Radiolabelled ligand
- Where
- Sweden
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Effect of Different Types of Aerobic Training on Diastolic Heart Failure Patients
Effect of Different Types of Aerobic Training on Peak VO2 and Ejection Fraction for Diastolic Heart Failure Patients; a Comparative Randomized Control Trial
Background: Heart failure is described by a lack of confirmed efficient therapies and exercise intolerance. Physical activity is related to a lower risk of adverse cardiovascular consequences, involving heart failure.
- Trial name
- NCT05637125
- Testing
- aerobic exercise for upper limb, aerobic exercise for lower limb
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Beni-Suef University
Impaired Left Ventricular Ejection Fraction
Validation of Kinocardiography, New Technology for Cardiac Linear and Torsional Contractility Measurement, to Assess Heart Failure Patient With Low Ejection Fraction
Measuring cardiac contractility is commonly realized with gold standard echocardiography or MRI. Portable devices to measure this contractility are not available as for rhythm and electric function assessment.
- Trial name
- NCT03157115
- Testing
- Kinocardiography
- Where
- Belgium
- Volunteers
- 130 people
- Sponsor
- Brugmann University Hospital
Heart Failure, Preserved Ejection Fraction
Real-world Study to Describe the Effectiveness and Safety Outcomes of Jardiance in Chinese Patients With Heart Failure and Preserved Ejection Fraction
The main objective of the study is to describe the effectiveness and safety outcomes among Chinese hospitalized heart failure with preserved ejection fraction (HFpEF) patients initiating Jardiance® in the real-world setting.
- Trial name
- NCT07047508
- Volunteers
- 3,000 people
- Sponsor
- Boehringer Ingelheim
Heart Failure
Improving Goal Directed Medical Therapy for Device Clinic Patients With Reduced EF at UOHI: a QI Initiative (VIGILANT)
This is a quality improvement initiative with the goal of optimizing heart failure (HF) patients seen through the outpatient cardiac implantable electronic device clinic at the University of Ottawa Heart Institute (UOHI).
- Trial name
- VIGILANT (NCT05085249)
- Where
- Canada
- Volunteers
- 2,479 people, healthy volunteers welcome
- Sponsor
- Ottawa Heart Institute Research Corporation
Heart Failure With Reduced Ejection Fraction
First in Humans to Evaluate Collagen Patches With Stem Cells in Patients With Ischemic Left Ventricular Dysfunction
It´s a first open-label trial in humans to evaluate the safety and efficacy of epicardial delivery of collagen patches with adipose-derived stem cells in patients with ischemic heart disease and left ventricular dysfunction that…
- Trial name
- CARDIOMESH (NCT03746938)
- Testing
- VB-C01
- Where
- 2 sites in Spain
- Volunteers
- 10 people
- Sponsor
- Viscofan
HFpEF - Heart Failure With Preserved Ejection Fraction, HFmrEF
US Benchmarking Clinical Study
The goal of this observational study is to measure shear wave velocity (SWV) in patients with non-reduced left ventricular ejection fraction (LVEF) heart failure and left ventricular hypertrophy, with or without transthyretin…
- Conditions
- HFpEF - Heart Failure With Preserved Ejection Fraction, HFmrEF, ATTR-CM (Transthyretin Amyloid Cardiomyopathy), Left Ventricular Hypertrophy
- Trial name
- EMS-CT-1 (NCT07215715)
- Where
- 3 sites in United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- eMyosound SAS
Heart Failure
Effect of Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Reduced Ejection Fraction
This was a randomized, double-blinded, placebo-controlled, multiple-dose study in subjects with stable heart failure (HF) with reduced ejection fraction (HFrEF).
- Trial name
- NCT02788747
- Testing
- 4 mg elamipretide, 40 mg elamipretide
- Where
- 15 sites in Italy, Netherlands and 1 more
- Volunteers
- 71 people
- Sponsor
- Stealth BioTherapeutics Inc.
Heart Failure With Preserved Ejection Fraction (HFPEF), Left Ventricular End Diastolic Pressure (LVEDP)
Evaluation of Left Ventricular Filling Pressures During Exercise
Heart failure with preserved ejection fraction (HFPEF) is common and is a real public health issue. Diagnosis, especially when there are no congestive signs, is difficult.
- Trial name
- PREFFORT (NCT01714752)
- Testing
- measure of left ventricular and diastolic pressure at exercise
- Where
- France
- Volunteers
- 60 people
- Sponsor
- French Cardiology Society
Acute Heart Failure With Reduced Left Ventricular Ejection Fraction
Telemonitoring to Optimize Medication Titration for Heart Failure: a Feasibility Study
Problem: Aggressive titration of guideline-directed medical therapy is the cornerstone of heart failure management to reduce heart failure related hospitalization and mortality.
- Trial name
- TOM-HF (NCT07016815)
- Testing
- Wearable wrist heart rate and activity monitor, Bluetooth enabled body weight scale with bioimpedance analysis, Bluetooth enabled electronic blood pressure device
- Where
- 2 sites in Hong Kong
- Volunteers
- 80 people
- Sponsor
- Chinese University of Hong Kong
Heart Failure With Preserved Ejection Fraction, Heart Diseases
Heart Failure With Preserved Ejection Fraction: Evaluation and Recognition by CMR
Heart failure with preserved ejection fraction (HFpEF) is a common and growing condition with a poor prognosis but the pathophysiology and management are still being investigated.
- Trial name
- PREFER-CMR (NCT05114785)
- Testing
- Multi Parametric Cardiac Magnetic Resonance
- Volunteers
- 100 people
- Sponsor
- University of East Anglia
Chagas Cardiomyopathy, Heart Failure
A Randomized Trial of Carvedilol in Chronic Chagas Cardiomyopathy
Chronic Chagas cardiomyopathy causes substantial morbidity and mortality in Latin America. Whether RAS inhibitors and beta-blockers are safe and beneficial has been challenged because of the lack of formal trials.
- Conditions
- Chagas Cardiomyopathy, Heart Failure, Dilated Cardiomyopathy
- Trial name
- NCT01557140
- Testing
- RASi plus carvedilol
- Where
- Brazil
- Volunteers
- 42 people
- Sponsor
- Federal University of Minas Gerais